Company intelligence / Profile preview

Calyxo

Pleasanton, California, United Statescalyxoinc.com ↗

Ownership: Private
Development stage: Commercial

Overview

Calyxo’s CVAC System is FDA-cleared and commercially available for minimally invasive kidney stone removal. Clinical studies—including randomized controlled trials—demonstrate that the SURE procedure using CVAC achieves superior stone clearance rates compared to standard ureteroscopy, with 97% volumetric clearance reported and over 10,000 patients treated as of April 2025. The second-generation system was launched in 2024 and has seen rapid adoption among urologists.

Therapeutic areas: Nephrology
Modalities: DeviceNon-pharmacological therapy (minimally invasive surgical device)
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on Calyxo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calyxo.

Explore the full profile